GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Cyclically Adjusted PS Ratio

SZLSF (StageZero Life Sciences) Cyclically Adjusted PS Ratio : 0.03 (As of May. 30, 2025)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Cyclically Adjusted PS Ratio?

As of today (2025-05-30), StageZero Life Sciences's current share price is $0.003. StageZero Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.11. StageZero Life Sciences's Cyclically Adjusted PS Ratio for today is 0.03.

The historical rank and industry rank for StageZero Life Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

SZLSF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.13   Med: 1.94   Max: 12.25
Current: 0.36

During the past years, StageZero Life Sciences's highest Cyclically Adjusted PS Ratio was 12.25. The lowest was 0.13. And the median was 1.94.

SZLSF's Cyclically Adjusted PS Ratio is ranked better than
87.12% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.07 vs SZLSF: 0.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

StageZero Life Sciences's adjusted revenue per share data for the three months ended in Sep. 2024 was $0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.11 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


StageZero Life Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for StageZero Life Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Cyclically Adjusted PS Ratio Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 2.75 6.49 2.39 0.50

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.44 0.40 0.33 0.36

Competitive Comparison of StageZero Life Sciences's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, StageZero Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

StageZero Life Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

StageZero Life Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.003/0.11
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, StageZero Life Sciences's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.004/127.2847*127.2847
=0.004

Current CPI (Sep. 2024) = 127.2847.

StageZero Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.161 99.394 0.206
201412 0.097 98.367 0.126
201503 0.098 99.789 0.125
201506 0.109 100.500 0.138
201509 -0.131 100.421 -0.166
201512 0.000 99.947 0.000
201603 0.019 101.054 0.024
201606 0.055 102.002 0.069
201609 0.013 101.765 0.016
201612 0.028 101.449 0.035
201703 0.018 102.634 0.022
201706 0.009 103.029 0.011
201709 0.004 103.345 0.005
201712 0.004 103.345 0.005
201803 0.000 105.004 0.000
201806 0.001 105.557 0.001
201809 0.005 105.636 0.006
201812 0.004 105.399 0.005
201903 0.004 106.979 0.005
201906 0.001 107.690 0.001
201909 0.001 107.611 0.001
201912 0.001 107.769 0.001
202003 0.001 107.927 0.001
202006 0.001 108.401 0.001
202009 0.031 108.164 0.036
202012 0.043 108.559 0.050
202103 0.038 110.298 0.044
202106 0.006 111.720 0.007
202109 0.009 112.905 0.010
202112 0.017 113.774 0.019
202203 0.013 117.646 0.014
202206 0.008 120.806 0.008
202209 0.008 120.648 0.008
202212 0.007 120.964 0.007
202303 0.007 122.702 0.007
202306 0.006 124.203 0.006
202309 0.006 125.230 0.006
202403 0.004 126.258 0.004
202406 0.003 127.522 0.003
202409 0.004 127.285 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


StageZero Life Sciences  (OTCPK:SZLSF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


StageZero Life Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.